Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.985
-0.015 (-0.75%)
May 15, 2026, 12:10 PM EDT - Market open
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 226 employees as of December 31, 2025. The number of employees increased by 13 or 6.10% compared to the previous year.
Employees
226
Change (1Y)
13
Growth (1Y)
6.10%
Revenue / Employee
$337,969
Profits / Employee
$67,841
Market Cap
159.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 226 | 13 | 6.10% | 226 | 0 |
| Dec 31, 2024 | 213 | 5 | 2.40% | 213 | 0 |
| Dec 31, 2023 | 208 | 11 | 5.58% | 208 | 0 |
| Dec 31, 2022 | 197 | -9 | -4.37% | 193 | 4 |
| Dec 31, 2021 | 206 | -1 | -0.48% | 202 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Immunic | 92 |
| Pyxis Oncology | 56 |
| Korro Bio | 49 |
| TuHURA Biosciences | 22 |
| Black Diamond Therapeutics | 21 |
| AN2 Therapeutics | 21 |
| Spruce Biosciences | 8 |
PLX News
- 2 days ago - Protalix BioTherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 2 days ago - Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - PRNewsWire
- 9 days ago - Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - PRNewsWire
- 2 months ago - Protalix BioTherapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - PRNewsWire
- 2 months ago - Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - PRNewsWire
- 2 months ago - Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio - TheFly
- 2 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - GlobeNewsWire